SYSTEMS AND METHODS FOR USE BY AN IMPLANTABLE MEDICAL DEVICE FOR CONTROLLING MULTI-SITE CRT PACING IN THE PRESENCE OF ATRIAL TACHYCARDIA

• US 20110319953A1
• Filed: 05/16/2011
• Published: 12/29/2011
• Est. Priority Date: 06/24/2010
• Status: Active Grant

• Current Assignee: Pacesetter Incorporated (Abbott Laboratories)
• Original Assignee: Pacesetter Incorporated (Abbott Laboratories)
• Inventors: More, Rohan A., Hellman, Heidi, Ostrow, Eliot L., Levine, Paul A., Reed, Derrick W.
• Granted Patent: US 8,332,033 B2
• Time in Patent Office: Days
• US Class Current: 607/14
• CPC Class Codes: A61N 1/3624 occurring in the atrium, i.e. atrial tachycardia
• CPC Class Codes: A61N 1/3684 for stimulating the heart at multiple sites of the ventricle or the atrium
• CPC Class Codes: A61N 1/36842 Multi-site stimulation in the same chamber
• CPC Class Codes: A61N 1/36843 Bi-ventricular stimulation
• CPC Class Codes: A61N 1/3688 configured for switching the pacing mode, e.g. from AAI to DDD

Abstract

Systems and methods are provided for use by implantable medical devices equipped to deliver multi-site left ventricular (MSLV) pacing. Sequential MSLV is associated with a relatively long post-ventricular atrial blanking (PVAB) period that might limit the detection of pathologic rapid organized atrial tachycardias (OAT). In one example, sequential MSLV cardiac resynchronization therapy (CRT) pacing is delivered within a tracking mode. A possible atrial tachycardia is detected based on the atrial rate exceeding an atrial tachycardia assessment rate (ATAR) threshold. The device then switches to either single-site LV pacing or simultaneous MSLV pacing, thereby effectively shortening the PVAB to detect additional atrial events that might otherwise be obscured, and thereby permitting the device to more reliably distinguish OATs (such as atrial flutter) from sinus tachycardia. The device may also employ an automatic mode switch (AMS) threshold set higher than the ATAR threshold for use in switching from tracking modes to nontracking modes.

Claims

1. A method for use by an implantable cardiac rhythm management device equipped to selectively deliver multi-site left ventricular (MSLV) pacing within a patient, the method comprising:

delivering non-simultaneous MSLV pacing to the heart of the patient within a tracking mode;

assessing the atrial rate of the patient; and

comparing an atrial rate against an atrial tachycardia assessment rate threshold (ATAR) and, if the atrial rate exceeds the ATAR threshold, switching from non-simultaneous MSLV pacing to one of substantially simultaneous MSLV pacing and single-site LV pacing to facilitate recognition of organized atrial arrhythmias (OATs).

2. The method of claim 1 wherein delivering non-simultaneous MSLV pacing to the heart of the patient within a tracking mode includes delivering sequential MSLV pacing.

3. The method of claim 1 wherein non-simultaneous MSLV pacing is switched to single-site LV pacing.

4. The method of claim 1 wherein non-simultaneous MSLV pacing is switched to substantially simultaneous MSLV pacing.

5. The method of claim 4 further including comparing the atrial rate against an automatic mode switch (AMS) threshold that is higher than the ATAR threshold and, if the atrial rate exceeds the AMS threshold, switching from the tracking mode to a nontracking mode.

6. The method of claim 5 wherein the ATAR threshold is set in the range of 90 to 150 beats per minute (bpm).

7. The method of claim 5 wherein the AMS threshold is set in the range of 170 bpm to 300 beats per minute (bpm).

8. The method of claim 5 wherein a post-ventricular atrial blanking (PVAB) interval is applied to an atrial sensing channel and wherein the PVAB is significantly shorter during simultaneous MSLV pacing than during substantially simultaneous MSLV pacing.

9. The method of claim 5 wherein, while the atrial rate is above the ATAR threshold but not above the higher AMS threshold, the device discriminates the atrial rhythm to distinguish sinus rhythm from an OAT.

10. The method of claim 9 wherein discriminating the atrial rhythm includes:

examining atrial events detected on an atrial sensing channel to detect a bigeminal pattern indicative of far field R-wave (FFRW) sensing on the atrial channel; and

in response detection of the bigeminal pattern, identifying the atrial rhythm as sinus rhythm.

11. The method of claim 10 further including confirming the bigeminal pattern indicative of FFRW sensing based on atrial event waveform morphology.

12. The method of claim 10 wherein, in response to the identification of the atrial rhythm as sinus rhythm, switching back to non-simultaneous MSLV pacing if the device is currently delivering substantially simultaneous MSLV pacing.

13. The method of claim 9 wherein discriminating the atrial rhythm to distinguish sinus rhythm from an OAT includes:

detecting a degree of stability in atrial event intervals detected on an atrial sensing channel during single-site LV pacing;

detecting the morphology of atrial events within the atrial sensing channel during single-site LV pacing; and

distinguishing OAT from sinus rhythm based on one or more of the degree of stability in atrial event intervals and the morphology of the atrial events.

14. The method of claim 13 wherein, in response to the identification of the atrial rhythm as OAT, switching to a nontracking mode while delivering substantially simultaneous MSLV pacing.

15. The method of claim 14 further including:

suppressing pacing and detecting a conduction pattern indicative of intrinsic conduction through the atrioventricular (AV) node of the heart of the patient; and

in response to detection of the conduction pattern, switching to non-simultaneous MSLV pacing while continuing a nontracking mode.

16. The method of claim 15 further including:

periodically switching back to substantially simultaneous MSLV pacing to determine whether OAT is still present and, if not, delivering non-simultaneous MSLV pacing.

17. The method of claim 16 wherein periodic returns to substantially simultaneous MSLV pacing to determine whether OAT is still present become less frequent over time.

18. The method of claim 15 wherein non-simultaneous MSLV pacing continues in the nontracking mode until OAT spontaneously terminates, then non-simultaneous MSLV pacing in the tracking mode resumes.

19. The method of claim 5 wherein, while the atrial rate is above the higher AMS threshold, the device discriminates the atrial rhythm based on atrial events detected on an atrial sensing channel to distinguish atrial fibrillation (AF) from an OAT.

20. The method of claim 19 wherein discriminating the atrial rhythm to distinguish AF from an OAT includes:

detecting a degree of stability in atrial event intervals detected on the atrial sensing channel;

detecting the morphology of atrial events within the atrial sensing channel; and

distinguishing OAT from AF based on one or more of the degree of stability in atrial event intervals and the morphology of the atrial events.

21. The method of claim 1 wherein delivering MSLV pacing to the heart of the patient includes delivering cardiac resynchronization therapy (CRT) using a multi-pole LV lead in conjunction with a right ventricular (RV) lead.

22. The method of claim 1 wherein a post-ventricular atrial blanking (PVAB) interval is applied to an atrial sensing channel and wherein delivering non-simultaneous MSLV pacing to the heart of the patient is performed to deliver pacing pulses subject to relatively long inter-electrode LV pacing delays sufficient to require a significantly longer PVAB interval than would be required with single-site LV pacing.

23. The method of claim 1 wherein a post-ventricular atrial blanking (PVAB) interval is applied to an atrial sensing channel and wherein delivering substantially simultaneous MSLV pacing to the heart of the patient is performed to deliver pacing pulses subject to relatively short inter-electrode LV pacing delays sufficient to allow a PVAB interval that is not significantly longer than would be required with single-site LV pacing.

24. A system for use by an implantable cardiac rhythm management device equipped to selectively deliver multi-site left ventricular (MSLV) pacing within a patient, the system comprising:

a single-site LV/MSLV pacing controller operative to control the delivery of pacing to the heart of the patient in one of a single-site LV pacing mode, a substantially simultaneous MSLV pacing mode and a non-simultaneous MSLV pacing mode; and

an atrial tachycardia detection system operative to detect a possible atrial tachycardia during non-simultaneous MSLV pacing based on an atrial tachycardia assessment rate (ATAR) threshold;

with

the pacing controller operative to switch from non-simultaneous MSLV pacing to one of the substantially simultaneous MSLV pacing mode and the single-site LV pacing mode while continuing in the tracking mode if the atrial rate exceeds the ATAR threshold.

25. A system for use by an implantable cardiac rhythm management device equipped to selectively deliver multi-site left ventricular (MSLV) pacing within a patient, the system comprising:

means for delivering non-simultaneous MSLV pacing to the heart of the patient within a tracking mode;

means for assessing the atrial rate of the patient; and

means for comparing an atrial rate against an atrial tachycardia assessment rate threshold (ATAR) and, if the atrial rate exceeds the ATAR threshold, switching from non-simultaneous MSLV pacing to one of a substantially simultaneous MSLV pacing and single-site LV pacing to enable recognition of organized atrial arrhythmias (OATs).